Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT01092273
  4. Details
NCT01092273 Clinical Trial

Bimatoprost Versus Travoprost at Cairo University

Glaucoma Clinical Trial

Official title:
Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01092273
Other study ID # Prostaglandins-Cairo-1A
Secondary ID
Status Completed
Phase N/A
First received March 23, 2010
Last updated March 23, 2010

Study information
Verified date January 2008
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority Egypt:Al Nour Eye Hospital Medical Committee
Study type Observational

Clinical Trial Summary

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Both
Age group 20 Years to 72 Years
Eligibility Inclusion Criteria:

- Glaucoma and Ocular Hypertension

Exclusion Criteria:

- Any ocular disease or medication that may raise the intraocular pressure.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Egypt Cairo University Cairo

Sponsors (1)
Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percentage of intraocular pressure lowering of bimatoprost versus travoprost.
Secondary Rate of development of complications.
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A

External Links